|
Published by: CHI Insight Pharma Reports
Published: Jan. 1, 2008 - 140 Pages
Table of Contents
- Chapter 1
- A BRIEF INTRODUCTION TO OPHTHALMOLOGY AND ITS MARKETS
- 1.1. The Eye and Its Disorders
- 1.2. The Ophthalmology Market
- 1.3. High Unmet Medical Need and Scientific Challenges
- Chapter 2
- THE HUMAN EYE: A UNIQUE THERAPEUTIC TARGET
- 2.1. Anatomy of the Visual Apparatus
- 2.2. Characterizing and Quantifying Vision
- 2.3. Eye Surgery
- Surgery for the Inner Eye
- Surgical Correction of Opacification or Refractive Deviations
- 2.4. Ophthalmological Drug Delivery: Barriers and Strategies
- Chapter 3
- DISORDERS OF THE ANTERIOR EYE: WHAT YOU CAN SEE IS NOT ALWAYS EASY TO TREAT
- 3.1. Dry Eye Syndrome
- Existing Products for Dry Eye
- Restasis
- Advanced-Stage Investigational Drugs for Dry Eye
- Early Experimental Therapeutic and Diagnostic Approaches to Dry Eye
- 3.2. Allergic Conjunctivitis
- New Developments
- 3.3. Corneal Lesions and Dystrophy
- 3.4. Superficial Eye Infections
- Infectious Conjunctivitis and Other "Simple" Anterior Eye Infections
- AzaSite: The First Ophthalmic Azithromycin
- Antibiotic and Combination Products in Development
- 3.5. Tropical Eye Infections Make Inroads
- Atypical Keratitis: A Growing Problem in Temperate Climate Zones
- Trachoma: The World's Leading Cause of Preventable Blindness
- River Blindness
- 3.6. Cataracts: Aging and Denaturation of the Lens
- A Sector Dominated by Surgery
- An Uphill Struggle for Drug Development
- Pharmacoprevention for Posterior Capsule Opacification
- Lens Regeneration and Tissue Biotechnology
- 3.7. Glaucoma: Pressure in the Front, Neurodegeneration in the Back of the Eye
- Drugs for Intraocular Pressure Reduction
- The Current Drug Landscape for Glaucoma
- New Developments in the Glaucoma Drug Field
- Chapter 4
- DISORDERS OF THE POSTERIOR EYE: AT THE SITE OF VISION
- 4.1. Vitrectomy: Radical Back-Eye Surgery for Multiple Causes
- Vitreous Replacements
- Preventing Formation of Cataracts as a Complication of Vitrectomy
- Vitrase/Vitragan: A Potential Alternative to Vitrectomy for Hemorrhages
- 4.2. Diabetic Retinopathy and Retinal Vein Occlusion: A Lifestyle Disorder That Blinds
- Laser Photocoagulation
- Triamcinolone: Not Approved, but Widely Used, for DME
- Ruboxistaurin: A Troubled Oral Drug Candidate for DME
- More Experimental Drug Candidates for Retinopathy: The New and the Old
- 4.3. Age-Related Macular Degeneration: The Leading Cause of Blindness in the Industrialized World
- Blood Vessel Sensitization to Phototherapy in Wet AMD
- Visudyne: The Pioneer
- Photrex and Optrin: 2 Follow-Up Photosensitizers
- Biotechnology Anti-VEGF Products: Rise of a Class
- Macugen
- Lucentis
- Avastin: Off-Label Use in AMD and the Supply Restrictions Controversy
- Follow-Up Developments in Ocular VEGF Control
- Beyond VEGF: A Failure, and Many Hopes
- Noninvasive Clinical Product Developments for AMD
- Vigorous Preclinical and Patenting Activity Indicates More Approaches Under Way
- 4.4. Retinitis Pigmentosa: The Most Frequent Inherited Eye Disease
- 4.5. Intraocular Melanoma and Retinoblastoma: Posterior Eye Oncology
- Choroidal Melanoma
- Retinoblastoma
- Chapter 5
- SIZE, STRUCTURE, AND DYNAMICS OF THE OPHTHALMOLOGICAL PHARMACEUTICAL MARKET
- 5.1. Small Innovators, Large Marketers
- Alcon Laboratories
- Allergan
- Bausch & Lomb
- Senju Pharmaceutical
- Fovea Pharmaceuticals
- ISTA Pharmaceuticals
- MacuSight
- Novagali Pharma
- Ocularis Pharma
- OSI Eyetech
- OPKO Health
- Othera Pharmaceuticals
- Sirion Therapeutics
- 5.2. A Habitat for Specialized CROs
- Iris Pharma and Clirophtha
- PharmaNet Ophthalmology Group
- Rx Development Resources
- Global Clinical Trials Ophthalmology Research Services
- 5.3. Ophthalmological Market Dynamics and its Drivers
- Demographics
- Lifestyle
- Capital Flows into the Ophthalmological Drug Development Market
- 5.4. Modeling the Ophthalmological Drug Market: Perspectives for 2015-2020
- Chapter 6
- EXPERT INTERVIEWS: A VIRTUAL ROUNDTABLE
- Cedric Francois, MD, PhD
- President and CEO
- Potentia Pharmaceuticals, Louisville, KY
- Avner Ingerman, MD
- Vice President and Ophthalmology Team Leader
- Regeneron Pharmaceuticals, Tarrytown, NY
- Samuel Reich
- Executive Vice President of Ophthalmologics
- OPKO Health
- Miami, FL
- Roger Vogel, MD
- Cofounder and Chief Medical Officer
- Sirion Therapeutics, Tampa, FL
- REFERENCES
- COMPANY INDEX WITH WEB ADDRESSES
- Tables
- Table 3.1. Selected Artificial Tear Products Marketed in the United States and Europe
- Table 3.2. Advanced Drug Candidates for Dry Eye Syndrome
- Table 3.3. Antihistamines and Steroids for Topical Ocular Use in Allergic Conjunctivitis
- Table 3.4. Newer Drugs for Intraocular Pressure Reduction Currently Used in the United States
- Table 4.1. Sales and Revenue Figures for Visudyne and US Sales Share, 2000-2006
- Table 4.2. Recent Patent Publications for Retinitis Pigmentosa
- Table 5.1. Selected Alcon IP Documents Directed at Glaucoma and Published in 2006
- Table 5.2. Allergan Net Sales for Selected Prescription OpHthalmology Drugs, 2002-2006
- Table 5.3. Fovea Pharmaceuticals' Ophthalmological Drug Pipeline
- Table 5.4. The Current US Prescription Ophthalmological Drug Market and its Projected Development Through 2015-2020
- Figures
- Figure 2.1. A Cross-Sectional Schematic of the Human Eye
- Figure 3.1. Lens Transparency, Lens Aging, and Cataract Formation
- Figure 3.2. Fluid Formation and Outflow Through the Trabecular Meshwork
- Figure 4.1. Visual Acuity Changes in the US-European Phase III TAP Study Program for Visudyne
AbstractThe ophthalmology market, although a relatively small niche in the pharmaceutical industry, is more than worthwhile to track for multiple reasons:
It is growing dynamically, and will likely continue this development unbroken for the next 2 or 3 decades.
It offers scientific challenges that are definitely tough but not insurmountable, with the paths to success already discernible.
It is a market that analysts and investors can understand. Severe eye diseases are debilitating but not terminal conditions, and therefore most people know at least 1 person with severe vision impairment and can sympathize—which on the whole creates a more favorable basis for investments.
Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets provides a cutting-edge review of the challenges, achievements, and perspectives that characterize the inseparable therapeutic triad of ophthalmological pharmacology, surgery of the visual tract, and implantable ophthalmological medical devices. At annual sales of less than $10 billion, this is a niche segment by the standards of the drug industry; however, it is a highly prestigious and profitable field. Because nothing that concerns intervention with the visual system is trivial, highly innovative specialist companies dominate development on the pharmacological as well as on the drug delivery side, which is immensely important in ophthalmological medicine.
Specifically, this report covers:
- A thorough therapeutic pipeline analysis
- Company profiles, including shifts in the corporate landscape since 2000
- A full discussion of eye disorders and potential treatments
- Current market dynamics
- Market predictions through 2015
- Expert commentary from leaders in the field
The market for prescription drugs to treat eye disorders will experience considerable and consistent growth throughout the next 10 years. The partial table below shows some of the research and development programs that are part of the growing field.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
